Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06895343 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants | PHASE1 | ACTIVE NOT_RECRUITING | 100 | — | — | Apr 3, 2025 | Nov 1, 2026 | Mar 2, 2026 | 2 | United States |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-701
Tmax of ABBV-701
(β) of ABBV-701
(t1/2) of ABBV-701
AUCt of ABBV-701
AUCinf of ABBV-701
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose A or placebo. |
| Part 1: Group 2 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose B or placebo. |
| Part 1: Group 3 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 1: Group 4 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose D or placebo. |
| Part 1: Group 5 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 6 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 2: Group 7 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 8 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose C or placebo. |
| Part 3: Group 9 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose E or placebo. |
| Part 3: Group 10 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 11 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Part 4: Group 12 ABBV-701 or Placebo | EXPERIMENTAL | Participants will receive a single dose of either ABBV-701 Dose F or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-701 | DRUG | Subcutaneous |
| Placebo | DRUG | Subcutaneous |
Inclusion Criteria: * Body weight is ≥ 35 kg and BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG * Part 2 and Part 4 only:...